SC
ABBV icon

Shuttleworth & Co’s AbbVie ABBV Stock Holding History

Shuttleworth & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.42M Buy
13,604
+181
+1% +$38.9K 2.74% 9
2026
Q1 		$2.92M Buy
13,423
+129
+1% +$28.6K 2.64% 8
2025
Q4 		$3.04M Buy
13,294
+25
+0.2% +$5.7K 2.78% 6
2025
Q3 		$3.07M Buy
+13,269
New +$2.7M 2.79% 7

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Shuttleworth & Co's ABBV Position: Q2 2026 in Review

Shuttleworth & Co increased its AbbVie (ABBV) stake by 1.3% in Q2 2026, buying an estimated $38.9K and bringing the position to 13,604 shares worth $3.42M. The position accounts for 2.74% of the portfolio, ranked #9.

Shuttleworth & Co first reported a position in ABBV in Q3 2025 and has held it in 4 quarters since. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Shuttleworth & Co held 13,604 shares of AbbVie worth $3.42M as of Q2 2026.
  • Shuttleworth & Co bought 181 AbbVie shares in Q2 2026, an estimated $38.9K.
  • AbbVie made up 2.74% of Shuttleworth & Co's portfolio in Q2 2026, its #9 holding.
  • Shuttleworth & Co first reported a position in AbbVie in Q3 2025 and has held it in 4 quarters since.
  • 4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Shuttleworth & Co's 13F filing for Q2 2026, filed 5 Aug 2026.